Phase 3 BRIGHT Study in Patients With Fabry Disease

Jack Johnson, Co-Founder and Executive Director of the Fabry Disease Support and Information Group, and VP of the Fabry International Network, discusses the phase 3 BRIGHT study testing Elfabrio (pegunigalsidase alfa-iwx) in patients with Fabry disease.    ...

AAV Gene Therapy in Patients With Gaucher Disease

Reena Sharma, MD, Salford Royal Hospital and University of Manchester, UK, discusses clinical data from a clinical trial testing an AAV gene therapy in patients with Gaucher disease.   Clarification (around 8:52): *malignancies Gaucher disease refers to a group...

Effects of Inebilizumab to Treat Myasthenia Gravis

Richard Nowak, MD, and Director of Myasthenia Gravis Clinic at Yale University, discusses data from the MINT study for myasthenia gravis (MG).     MG is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. The...